Anatomical / histological sub-stage
IA1 — non-aggressive type, limited to a polyp or confined to the endometrium
IA2 — non-aggressive type, < 50% myometrial invasion, no or focal LVSI
IA3 — low-grade endometrioid, limited to the uterus and ovary (per FIGO criteria)
IB — non-aggressive type, ≥ 50% myometrial invasion, no or focal LVSI
IC — aggressive type, limited to a polyp or confined to the endometrium
IIA — non-aggressive type with cervical stromal invasion
IIB — non-aggressive type with substantial LVSI
IIC — aggressive type with any myometrial invasion
IIIA1 — spread to the ovary or fallopian tube (not meeting IA3)
IIIA2 — involvement of the uterine subserosa or spread through the serosa
IIIB1 — metastasis or direct spread to the vagina and/or parametria
IIIB2 — metastasis to the pelvic peritoneum
IIIC1(i) — pelvic lymph node micrometastasis
IIIC1(ii) — pelvic lymph node macrometastasis
IIIC2(i) — para-aortic lymph node micrometastasis (± pelvic nodes)
IIIC2(ii) — para-aortic lymph node macrometastasis (± pelvic nodes)
IVA — invasion of the bladder and/or bowel mucosa
IVB — abdominal peritoneal metastasis beyond the pelvis
IVC — distant metastasis (nodes above the renal vessels, lung, liver, brain, bone)
Molecular classification (if available)
POLEmut — pathogenic POLE exonuclease-domain mutation
MMRd — mismatch-repair deficient
NSMP — no specific molecular profile
p53abn — abnormal p53 immunohistochemistry
Evidence
[1] Original publication
Berek JS, Matias-Guiu X, Creutzberg C, et al. FIGO staging of endometrial cancer: 2023. Integrates histological type, lymphovascular space invasion, and — where available — molecular classification. Early-stage POLEmut disease is assigned Stage IAmPOLEmut and early-stage p53abn disease with myometrial invasion is assigned Stage IICmp53abn.
International Journal of Gynaecology and Obstetrics, 2023
Last reviewed: 2026-10
Report an error in this calculator